Biocytogen Pharmaceuticals signs a License Agreement With Pheon Therapeutics

Exclusive License Agreement for an Oncological Target Antibody to Develop Best-In-Class ADC

Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a global biotech company focusing on the discovery of novel antibody therapeutics, yesterday announced an antibody license agreement with Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) specialist developing next-generation ADCs for a wide range of hard-to-treat cancers. Under the terms of the agreement, Pheon will develop and commercialize an […]

Biocytogen signs Antibody Agreement with ADC Therapeutics

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) recently announced that it has entered into an evaluation and option agreement with ADC Therapeutics SA. Biocytogen will grant ADC Therapeutics a license to evaluate Biocytogen’s proprietary antibodies against three tumor targets, with an option to license selected antibodies at a later date for global ADC development and commercialization. […]